πŸ‡ΊπŸ‡Έ FDA
Patent

US 9603907

Dry powder formulations of dNase I

granted A61KA61K33/06A61K33/14

Quick answer

US patent 9603907 (Dry powder formulations of dNase I) held by Protalix Ltd. expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Protalix Ltd.
Grant date
Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K33/06, A61K33/14, A61K38/465, A61K38/47